Previous close | 24.67 |
Open | 24.56 |
Bid | 25.51 x 100 |
Ask | 25.56 x 100 |
Day's range | 24.51 - 25.85 |
52-week range | 4.82 - 26.24 |
Volume | |
Avg. volume | 1,220,221 |
Market cap | 2.034B |
Beta (5Y monthly) | 0.71 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.91 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 46.71 |
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences:
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on March 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 30,800 shares of its common stock and 15,400 restricted stock units ("RSUs") to three (3) new non-executive employees under the Avidity Biosci
Michael Maclean, Chief Financial Officer of Avidity Biosciences Inc (NASDAQ:RNA), sold 40,000 shares of the company on March 13, 2024, according to a recent SEC filing.